Circulating melanoma cells as a predictive biomarker

Journal of Investigative Dermatology

Volumn 133, Issue 6, 2013, Pages 1460-1462

  Karakousis, Giorgos ^a   Yang, Ruifeng ^a   Xu, Xiaowei ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD146 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; LACTATE DEHYDROGENASE; VEMURAFENIB;

CANCER PROGNOSIS; CIRCULATING TUMOR CELL; CONFIDENCE INTERVAL; HAZARD RATIO; HUMAN; LOG RANK TEST; LONG TERM SURVIVAL; MELANOMA CELL; METASTATIC MELANOMA; MOLECULAR WEIGHT; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SYSTEMIC THERAPY; TUMOR GROWTH;

EID: 84878544541     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.34     Document Type: Note

References (12)

1. Campoli MR, Chang CC, Kageshita T et al. (2004) Human high molecular weight-melanomaassociated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 24:267-96
2. Cristofanilli M, Budd GT, Ellis MJ et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781-91
3. Flaherty KT (2012) Targeting metastatic melanoma. Annu Rev Med 63:171-83
4. Flaherty KT, Infante JR, Daud A et al. (2012a) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694-703
5. Flaherty KT, Puzanov I, Kim KB et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-19
6. Flaherty KT, Robert C, Hersey P et al. (2012b) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-14
7. Hodi FS, O'Day SJ, McDermott DF et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-23
8. Khoja L, Loriqan P, Zhou C et al. (2013) Biomarker utility of circulating tumour cells in metastatic cutaneous melanoma. J Invest Dermatol 133:1582-90
9. Lipson EJ, Sharfman WH, Drake CG et al. (2013) Durable cancer regression off-treatment and effective re-induction therapy with an anti- PD-1 antibody. Clin Cancer Res 19:462-8
10. Sosman JA, Kim KB, Schuchter L et al. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-14
11. Xu X, Chen L, Guerry D et al. (2012) Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma. Clin Cancer Res 18:229-37
12. Xu X, Gimotty PA, Guerry D et al. (2008) Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis. Hum Pathol 39:901-9